Zogenix (ZGNX)

[TRUISM]

CAN ZOGENIX, INC. (NASDAQ:ZGNX) SURPRISE ANALYSTS THIS QUARTER?
on JUNE 2, 2015
Click For Link





Earnings surprises occur when a company’s actual reported earnings differ from the consensus analyst estimates. A positive or negative earnings surprise can often result in significant stock price movement immediately after the earnings announcement, but can also have a long-term effect as well.

In the most recent quarter, Zogenix, Inc. (NASDAQ:ZGNX) reported an earnings surprise of 38.46% when the firm last announced their results for the period ending on 2015-06-30. The actual earnings per share number of $-0.08 was $0.05 away from the consensus analyst number.

Zogenix, Inc. (NASDAQ:ZGNX) will next issue their quarterly earnings announcement on 2015-08-04. Brokerage firm analysts surveyed by Zacks research are estimating earnings of $0 per share. This is the consensus number calculated from the 5 polled analysts taken into consideration by Zacks. Institutions and investors alike will be closely monitoring estimate revisions of the EPS numbers leading up to the expected results date.

Stock Price Target

Sell-side firms covering the equity are estimating that the stock will reach $2.8 on a short-term basis. This is the mean estimate based on the 5 brokerage analysts surveyed by Zacks. The most bullish analyst sees the stock reaching 3.5 while the most conservative target is set at $2.5.

By simplifying the analyst ratings into a 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell, Zogenix, Inc. has a rating of 1.33 . This is the arithmetic mean of all the analyst estimates taken into consideration by Zacks. When the same analysts were polled three months ago, the rating was at 1.33.

Zogenix, Inc. (Zogenix) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. The Company’s product Sumavel DosePro offers needle-free subcutaneous administration of sumatriptan for the treatment of migraine and cluster headache in a pre-filled, single-use delivery system.

Its lead product candidate, Zohydro (hydrocodone bitartrate, formerly ZX002) is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain requiring opioid therapy. It completed Phase 3 development of Zohydro in 2011. Sumavel DosePro and Zohydro are used for the treatment options available to patients and physicians in the United States. Its second DosePro investigational product candidate, Relday, is a injectable formulation of risperidone for the treatment of schizophrenia. In May, 2012, it submitted a New Drug Application to the Food and Drug Administration (FDA).




Blessings to All

TRUTH